Direct Rx FDA Inspection Record
Direct Rx is an FDA-registered facility (FEI 3011690045) located in Dawsonville, GA, US. Registered operations: RELABEL; REPACK. RegDataLab tracks 3 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Jun 4, 2026: No Action Indicated (NAI)
- Inspections on record
- 3 (1 VAI, 2 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 21, latest Sep 29, 2026
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Jun 4, 2026 | No Action Indicated (NAI) | No citations listed |
| Dec 15, 2017 | No Action Indicated (NAI) | Returned drug products identified and held (21 CFR 211.204) |
| Aug 13, 2015 | Voluntary Action Indicated (VAI) | SOPs not followed / documented (21 CFR 211.100(b)) Prepared for each batch, include complete information (21 CFR 211.188) Written warehousing procedures established/followed (21 CFR 211.142) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Sep 29, 2026 | Class II | D-0107-2027 | Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged and Distributed by: Direct Rx… Subpotent Drug |
| Jun 22, 2026 | Class II | D-0617-2026 | DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60… CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit |
| Mar 7, 2025 | Class II | D-0567-2025 | Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by… and 1 more product CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. |
| Jan 31, 2025 | Class II | D-0364-2025 | CIPROFLOXACIN OPHTH SOLUTION, 0.3% 5mL bottle, Rx Only, Generic for CILOXAN, Packaged and… Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle |
| Aug 9, 2024 | Class II | D-0041-2025 | Ibuprofen 800mg, Generic for: Motrin, Each tablet contains: Ibuprofen, USP 800 mg… Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing. |
| Mar 22, 2023 | Class II | D-0507-2023 | Alprazolam C-IV, 0.5 mg, 30 Tabs per bottle, Rx only, Packaged and Distributed By: Direct… and 2 more products CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer. |
| Mar 13, 2023 | Class II | D-0476-2023 | Montelukast Sodium Tablets, USP, 10 mg Tablets, Rx Only, Packaged as: a) 30-count bottle… and 10 more products cGMP deviations |
| Nov 2, 2022 | Class II | D-0101-2023 | Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct… cGMP deviation: discontinue of stability support for product. |
| Sep 12, 2022 | Class II | D-1535-2022 | Triamcinolone Acetonide cream, 0.1%, 80 g tube, Rx only, Packaged and Distributed By… CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness. |
| May 13, 2022 | Class II | D-0888-2022 | Zonisamide Capsules USP, 100 mg, 90-count bottle, Rx Only, Packaged and Distributed By… CGMP Deviations: Gaps in the quality system in the Quality Control microbiology laboratory. |
FDA record score
48 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
22 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class II recall D-0107-2027, this FEI as the recalling firm | Sep 29, 2026 | 4 x 1 | 4 |
| Class II recall D-0617-2026, this FEI as the recalling firm | Jun 22, 2026 | 4 x 1 | 4 |
| Class II recall D-0567-2025, this FEI as the recalling firm | Mar 7, 2025 | 4 x 1 | 4 |
| Class II recall D-0364-2025, this FEI as the recalling firm | Jan 31, 2025 | 4 x 1 | 4 |
| Class II recall D-0041-2025, this FEI as the recalling firm | Aug 9, 2024 | 4 x 0.6 | 2.4 |
| Class II recall D-0507-2023, this FEI as the recalling firm | Mar 22, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-0476-2023, this FEI as the recalling firm | Mar 13, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-0101-2023, this FEI as the recalling firm | Nov 2, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-1535-2022, this FEI as the recalling firm | Sep 12, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0888-2022, this FEI as the recalling firm | May 13, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0893-2022, this FEI as the recalling firm | May 11, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0971-2022, this FEI as the recalling firm | May 5, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0650-2022, this FEI as the recalling firm | Mar 4, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0637-2022, this FEI as the recalling firm | Feb 17, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0714-2022, this FEI as the recalling firm | Dec 7, 2021 | 4 x 0.6 | 2.4 |
| Class II recall D-0829-2021, this FEI as the recalling firm | Sep 14, 2021 | 4 x 0.25 | 1 |
| Class II recall D-0300-2021, this FEI as the recalling firm | Mar 2, 2021 | 4 x 0.25 | 1 |
| Class II recall D-0058-2021, this FEI as the recalling firm | Oct 12, 2020 | 4 x 0.25 | 1 |
| Class II recall D-0016-2021, this FEI as the recalling firm | Jan 15, 2020 | 4 x 0.25 | 1 |
| Class II recall D-0018-2021, this FEI as the recalling firm | Apr 30, 2019 | 4 x 0.25 | 1 |
| Class II recall D-0032-2021, this FEI as the recalling firm | Mar 12, 2019 | 4 x 0.25 | 1 |
| Inspection classified VAI | Aug 13, 2015 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Direct Rx as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Direct Rx yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Direct Rx
- Location
- Dawsonville, GA (US)
- Registration Expires
- Dec 31, 2027
- Operations
- RELABEL; REPACK
- Source
- decrs